Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-06-14
2011-06-14
Bunner, Bridget E (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S324000, C930S050000, C930S120000, C930S141000
Reexamination Certificate
active
07960123
ABSTRACT:
The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis-markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PlGF, and sCD40L.
REFERENCES:
patent: 5744305 (1998-04-01), Fodor et al.
patent: 2509 063 (2005-06-01), None
patent: WO 2004046722 (2004-06-01), None
Heeschen et al, Jan. 2004. JAMA. 291(4): 435-441.
Ribatti et al, 2007. Pharmacological Reviews. 59: 185-205).
Stitt et al, 2005. Diabetes. 54(3): 785-794).
Cao et al, 1997. Biochemical and Biophysical Research Communications. 235: 493-498.
Van Regenmortel et al, 1998. Journal of Immunological Methods. 216: 37-48.
Blann et al, 2002. Clinical Science. 102: 187-194.
Varo et al. 2003. Circulation. 107: 2664-2669.
De Lemos et al (2005. Arterioscler Thromb Vasc Biol. 25: 2192-2196).
Prontera et al (2003. Clinical Chem. 49(9): 1552-1554).
Koito et al (2004; J. Biochem. 136: 831-837).
Pepys et al. 2003. J Clin Invest. 111: 1805-1812.
Luc et al, 2003. Arterioscler Thromb Vasc Biol. 23: 1255-1261.
Isotani, H. et al., “Plasma Brain Natriuretic Peptide Levels in Normotensive Type 2 Diabetic Pateints without Cardiac Disease,” Diabetes Care, vol. 23, No. 5, Jun. 2000, pp. 859-860.
Khaliq, A. et al., “Increased Expression of Placenta Growth Factor in Proliferative Diabetic Retinopathy,” Laboratory Investigation, vol. 78, No. 1, pp. 10-116, 1998.
Nielsen, L. et al., “N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea,” The European Journal of Heart Failure (2003) pp. 1-8.
Siebenhofer, A. et al., “Plasma N-terminal pro-brain natriuretic peptide in Type 1 diabetic patients with and without diabetic nephropathy,” Diabetic Medicine, 20, 535-539 (2003).
Yano, Y. et al., “Plasma Brain Natriuretic Peptide Levels in Normotensive Noninsulin-Dependent Diabetic Pateints with Microalbuminuria,” The Journal of Clinical Endocrinoloby & Metabolism, vol. 84, No. 7, pp. 2353-2356 (1999).
Beer, S. et al., “Impaired microvascular function is associated with raised plasma N-terminal pro-brain natriuretic peptide level in Type 2 diabetic patients,” Diabetologia, vol. 46, No. 2, Aug. 2003.
Cal, J. et al., “Activation of Vascular Endothelial Growth Factor Receptor-1 Sustains Angiogenesis and Bcl-2 Expression Via the Phosphatidylinositol 3-Kinase Pathway in Endohelial Cells,” Diabetes, vol. 52, Dec. 2003, p. 2959-2968.
Goede, P. et al., “Multifactorial Intervention an Cardiovascular Disease in Patients with Type 2 Diabetes,” The New England Journal of Medicine, vol. 348, No. 5, p. 363-393, Jan. 30, 2003.
Kilhovd, B. at al, “Serum Levels of Advanced Glycation End Products Are Increased in Patients with Type 2 Diabetes and Coronary Heart Disease,” Diabetes Care, vol. 22, No. 9, p. 1543-1548, Sep. 1999.
Mitamura, Y. et al., “Vitreous Levels of Placenta Growth Factor and Vascular Endothelial Growth Factor in Patients with Proliferative Diabetic Retinopathy,” Diabetes Care, vol. 25, No. 12, Dec. 2002, p. 2352.
Pelsers, M. et al., “Brain-and Heart-Type Fatty Acid-Binding Proteins in the Brain: Tissue Distribution and Clinical Utility,” Clinical Chemistry 50: 1568-1575, 2004.
Reddy, D. et al., “Utility of NT-BNP as a screening tool for cardiac dysfunction in patients with long-standing diabetes mellitus,” European Journal of Heart Failure Supplements, Elsevier, vol. 3, No. 1, Jun. 2004, p. 24.
Yngen, M. et al., “Enhanced P-selectin expression and increased soluble DC40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation,” Diabetologia (2004) 47:537-540.
Masshoshinkei (Peripheral Nerve), 2000, vol. 11, No. 1, pp. 29-34 (English abstract on p. 34).
Hess Georg
Horsch Andrea
Bunner Bridget E
Howard Zachary C
Roche Diagnostics Operations Inc.
LandOfFree
Multimarker panel based on PIGF for diabetes types 1 and 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multimarker panel based on PIGF for diabetes types 1 and 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multimarker panel based on PIGF for diabetes types 1 and 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712441